Image-guided therapy firm Brainlab is highlighting preliminary results from a study investigating the safety and efficacy of stereotactic body radiation therapy (SBRT) in the treatment of patients with prostate cancer using the company's ExacTrac patient position-monitoring device.
The study is being conducted by a group of international cancer centers; its principal investigator is Dr. Raymond Miralbell of the Centro Médico Teknon in Barcelona, Spain. Miralbell's group is using a fractionation protocol of 5 Gy times 7.25 Gy, delivered to two groups of patients (152 total) over two time schedules, with group A receiving treatment every other day for a total of nine days, and group B receiving treatment once a week for a total of 28 days.
All patients are positioned and monitored with ExacTrac, which requires no additional internal immobilization. The treatment plans were developed to deliver no more than 6.5 Gy per fraction to the urethra, Brainlab said.
Early analysis of the study results indicates that both groups experienced only mild urinary acute toxicities with complete resolution six weeks post-treatment, which suggests that the treatment protocols are safe, according to the firm.
